Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

59.22 -0.05 (-0.08%)
Official Closing Price Updated: 5:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
66 67 Next >
I ‘Tricked’ ChatGPT Into Picking Stocks to Buy. Here’s What It Said.
We asked ChatGPT to name various types of stocks to buy. Can the latest artificial intelligence craze get things right? 
Via InvestorPlace
Bristol Myers' Opdivo Shows Improved Clinical Benefits In Bladder Cancer At Three Years
Via Benzinga
Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate -274 Trial
From Bristol Myers Squibb
Via Business Wire
A Bearish Sign Appears On Bristol-Myers Squibb's Chart
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
These two companies each pay market-beating dividends to shareholders. 
Via The Motley Fool
What 5 Analyst Ratings Have To Say About Bristol-Myers Squibb
Via Benzinga
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap?
The company's biggest moneymakers are soon to lose patent protection. 
Via Investor's Business Daily
Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation (AFib) and its Symptoms
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb-Exelixis Highlight Three-Year Follow Up Data From Opdivo+Cabometyx Combo Therapy In Kidney Cancer
Via Benzinga
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
Bristol Myers Jumps On Fourth-Quarter Beat Strong Earnings Outlook
The company's outlook for 2023 profit topped forecasts by 11 cents at the midpoint. 
Via Investor's Business Daily
A Preview Of Bristol-Myers Squibb's Earnings
Via Benzinga
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb and Exelixis, Inc.
Via Business Wire
Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients
Via Benzinga
A Look At Pharma ETFs Post Q4 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study
From Bristol Myers Squibb
Via Business Wire
NeurAxis: Should You Buy This IPO?
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype. 
Via Talk Markets
2 Top Biotech Stocks to Buy in February
Biotech stocks aren't all created equal -- these two are the best of the bunch. 
Via The Motley Fool
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets
Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly
Via Benzinga
Could This Indication Provide a Lift for Bristol Myers Squibb's Stock?
Bristol Myers' Sotyktu recently moved one step closer to its first approval in the European Union. 
Via The Motley Fool
1 Company Bucks the Office REIT Trend With Higher Rents and Earnings
Life sciences companies may be more immune to work-from-home shifts. 
Via The Motley Fool
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb (BMY) Q4 2022 Earnings Call Transcript
BMY earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Bristol Myers Squibb Q4 Earnings And Revenues Surpass Estimates
Bristol Myers Squibb came out with quarterly earnings of $1.82 per share. 
Via Talk Markets
Revlimid Generic Competition Hurts Bristol Myers' Q4 Earnings, Issues Annual Outlook Within Expected Range
Via Benzinga
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
From Bristol Myers Squibb
Via Business Wire
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging. 
Via Benzinga
Bristol-Myers Squibb Unusual Options Activity For February 01
Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.